The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Status
Conditions
Treatments
Details and patient eligibility
About
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE. This study was to compare HAIC with FOLFOX with sorafenib who showed TACE-resistant.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnosed with HCC according to the European Association for the Study of the Liver (EASL) diagnostic criteria
- TACE failure/refractoriness by Liver Cancer Study Group of Japan (LCSGJ) criteria
- Without extrahepatic metastasis
- The following laboratory parameters:
Platelet count ≥ 60,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) >1,500/mm3
Exclusion criteria
- Known history of HIV
- History of organ allograft
- Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
- Serious non-healing wound, ulcer, or bone fracture
- Evidence of bleeding diathesis.
- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug
Trial design
Primary purpose
Allocation
Interventional model
Masking
114 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal